{"schemaVersion":1,"research":true,"symbol":"wst","name":"West Pharmaceutical Services","topic":"moat","path":"/stock/wst/moat","status":"published","version":3,"updatedAt":"2026-10-18T00:23:02.739Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"narrow","summary":"West has a narrow moat centered on proprietary containment technology, specialized manufacturing and regulatory integration with customers' drug products. Exclusive licenses and lengthy product development and approval processes support differentiation and probable switching friction. Actual price increases alongside growing demand support pricing power, but competitor comparisons, customer switching outcomes and long-term license protection are insufficient to establish a wide moat. West Vantage has less clearly demonstrated protection.","advantages":[{"mechanism":"intangible_assets","claim":"Exclusive licenses for certain proprietary products and processes, supported by research facilities and regulatory testing capabilities, provide a current differentiated offering. Growth in high-value components supports commercial relevance; it does not independently establish technological superiority.","durability":"Several-year development periods and customer and regulatory acceptance requirements make replication time-consuming. License duration, patent expiry and comparative product performance are undisclosed, limiting confidence in long-term protection.","risks":"Dependence on licensed technology, alternative delivery technologies and failure to meet customer quality expectations could weaken differentiation. New platforms and expanded services remain potential advantages until commercial outcomes establish them.","invalidation":"Loss of key exclusive rights without adequate substitutes, demonstrated replacement by equivalent competing products, or sustained high-value product demand losses despite growth in underlying customer markets would undermine this advantage.","competitors":[],"evidenceIds":["e1","e2","e3","e4","e5","e6","e7"],"counterEvidenceIds":["e8","e9"]},{"mechanism":"switching_costs","claim":"Customer acceptance and regulatory approval of drug products incorporating West components imply qualification friction and customer dependency. This is an inference from disclosed development and approval processes, rather than demonstrated switching costs or contractual lock-in.","durability":"Integration into regulated drug products can support continuing demand, reinforced by observed high-value component growth. The passages do not establish requalification requirements for changing an existing supplier or quantify customer retention.","risks":"Customers may qualify alternatives, and regulatory requirements also constrain West's own sourcing. Production failures can outweigh incumbency benefits. Actual cyber-related downtime demonstrates operational vulnerability.","invalidation":"Evidence that customers routinely replace qualified West components quickly and cheaply, or sustained customer losses to alternatives without meaningful qualification obstacles, would invalidate the switching-friction thesis.","competitors":[],"evidenceIds":["e3","e4","e5","e6","e7"],"counterEvidenceIds":["e10","e11"]}],"evidence":[{"id":"e1","sourceId":"filing-1","location":"Business / Intellectual Property","excerpt":"Certain key value-added and proprietary products and processes are exclusively licensed from Daikyo."},{"id":"e2","sourceId":"filing-1","location":"Business / Research and Development Activities","excerpt":"Research and Development Activities We maintain our own research-scale production facilities and laboratories for developing new products and offer contract engineering design and development services to assist customers with new product development."},{"id":"e3","sourceId":"filing-1","location":"Business / Quality control and regulatory testing capabilities","excerpt":"Our quality control, regulatory and laboratory testing capabilities are used to ensure compliance with applicable manufacturing and regulatory standards for primary and secondary pharmaceutical packaging components and drug delivery systems."},{"id":"e4","sourceId":"filing-1","location":"Business / Commercial development periods","excerpt":"Commercial development of our new products and services for medical and pharmaceutical applications commonly requires several years."},{"id":"e5","sourceId":"filing-1","location":"Business / Customer acceptance and regulatory approval","excerpt":"New products that we develop may require separate approval as medical devices, and products that are intended to be used in the packaging and delivery of pharmaceutical products are subject to both customer acceptance of our products and regulatory approval of the customers' products following our development period."},{"id":"e6","sourceId":"filing-2","location":"MD&A / Second-quarter 2026 HVP component sales","excerpt":"Sales of HVP components increased $65.5 million, or 18.4%, excluding foreign currency translation effects."},{"id":"e7","sourceId":"filing-2","location":"MD&A / HVP component demand and pricing drivers","excerpt":"This increase in HVP components sales was driven by continued strong customer demand for both Biologics and GLP-1 products as well as sales price increases."},{"id":"e8","sourceId":"filing-1","location":"Risk factors / Alternative technologies","excerpt":"The development of new or improved products, processes or technologies by other companies (such as needle-free injection technology) may reduce customer demand for our products or render some of our products or proposed products obsolete or less competitive."},{"id":"e9","sourceId":"filing-1","location":"Risk factors / Quality expectations and innovation","excerpt":"In addition, any failure or inability to meet increased customer quality expectations or to develop innovative products that address our customers' requests could cause a reduction in demand."},{"id":"e10","sourceId":"filing-1","location":"Risk factors / Replacement raw-material sources","excerpt":"Due to the stringent regulations and requirements of the FDA and other regulatory authorities regarding the manufacture of our products and the availability of such raw materials, we may not be able to quickly establish additional or replacement sources for these components or raw materials or do so without excessive cost."},{"id":"e11","sourceId":"filing-2","location":"MD&A / West Vantage cyber-related production downtime","excerpt":"These increases were partially offset by our revenue growth being negatively impacted by approximately $7 million from production downtime associated with the Company’s May 2026 cyber incident."},{"id":"e12","sourceId":"filing-1","location":"Business / Contract manufacturing differentiation and competition","excerpt":"We seek to differentiate ourselves by leveraging our global capabilities and reputation and by employing new technologies such as high-speed automated assembly, insert-molding, multi-shot precision molding, expertise with multiple-piece closure systems, and more recently scalable drug packaging and assembly solutions, which expands our competitive set to include CMO’s such as Sharp and PCI Pharma Services."},{"id":"e13","sourceId":"filing-2","location":"MD&A / Second-quarter 2026 volume, mix and price contributions","excerpt":"Volume and mix and sales price increases contributed $67.0 million and $30.3 million, respectively, of growth in the three months ended June 30, 2026."},{"id":"e14","sourceId":"filing-1","location":"MD&A / 2025 Proprietary Products operating profit","excerpt":"Proprietary Products – Proprietary Products operating profit increased by $79.4 million, or 13.7%, in 2025, including a favorable foreign currency translation impact of $20.9 million, due to the factors described above, most notably increased customer demand, primarily of high value components, higher plant absorption and sales price increases."},{"id":"e15","sourceId":"filing-1","location":"MD&A / 2025 Contract-Manufactured Products operating profit","excerpt":"Contract-Manufactured Products – Contract-Manufactured Products operating profit decreased by $8.9 million, or 12.3%, in 2025, including a favorable foreign currency translation impact of $1.4 million, due to the factors described above, most notably increased production costs."},{"id":"e16","sourceId":"filing-1","location":"Risk factors / Historical cost pass-through delays","excerpt":"While we generally attempt to pass along increased costs to our customers in the form of sales price increases, historically there has been a time delay between raw material and/or energy price increases and our ability to increase the prices of our products."},{"id":"e17","sourceId":"filing-1","location":"Risk factors / Competitive limits on price increases","excerpt":"In some circumstances, we may not be able to increase the prices of our products due to competitive pressure and other factors."},{"id":"e18","sourceId":"filing-2","location":"Unaudited condensed consolidated statements of income","excerpt":"and Subsidiaries (in millions, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net sales $ 872.3 $ 766.5 $ 1,717.2 $ 1,464.5 Cost of goods and services sold 543.1 492.6 1,091.6 958.7 Gross profit 329.2 273.9 625.6 505.8 Research and development 19.7 19.1 35.5 35.4 Selling, general and administrative expenses 117.6 95.9 217.1 183.9 Other expense (income) (Note 14) 12.8 5.2 16.8 25.8 Operating profit 179.1 153.7 356.2 260.7 Interest expense, net 2.6 0.1 4.5 0.5 Interest income (3.8) (3.6) (8.9) (7.7) Other nonoperating expense (income) 0.2 0.2 0.4 0.4 Income before income taxes and equity in net income of affiliated companies 180.1 157.0 360.2 267.5 Income tax expense 32.2 30.2 76.9 54.3 Equity in net income of affiliated companies (6.1) (5.0) (9.5) (8.4) Net income $ 154.0 $ 131.8 $ 292.8 $ 221.6 Net income per share: Basic $ 2.17 $ 1.82 $ 4.10 $ 3.06 Diluted $ 2.15 $ 1.82 $ 4.07 $ 3.05 Weighted average shares outstanding: Basic 70.8 72.2 71.4 72.3 Diluted 71.3 72.5 71.9 72.8 See accompanying notes to condensed consolidated financial statements."},{"id":"e19","sourceId":"filing-1","location":"Consolidated statements of cash flows / 2023–2025","excerpt":"and Subsidiaries for the years ended December 31, 2025, 2024 and 2023 (in millions) 2025 2024 2023 Cash flows from operating activities: Net income $ 493.7 $ 492.7 $ 593.4 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 168.6 151.8 133.7 Amortization 2.8 3.6 3.6 Stock-based compensation 23.8 18.7 23.3 Non-cash restructuring charges 5.4 — — Pension settlement charges — — 0.1 Loss on disposal of plant — — 11.6 Asset impairments 11.7 7.3 9.6 Deferred income taxes (13.7) (3.5) 37.5 Pension and other retirement plans, net 0.6 (2.0) (2.6) Equity in undistributed earnings of affiliates, net of dividends (10.5) (13.4) (14.3) Other, net (7.4) (4.7) 1.0 Changes in assets and liabilities: Decrease (increase) in accounts receivable 6.9 (58.8) 4.0 (Increase) decrease in inventories (62.8) 42.0 (13.5) Decrease (increase) in other current assets 9.7 (5.8) (21.3) Increase in accounts payable 17.9 2.9 4.4 Changes in other assets and liabilities 108.1 22.6 6.0 Net cash provided by operating activities 754.8 653.4 776.5 Cash flows from investing activities: Capital expenditures (285.9) (377.0) (362.0) Other, net — (1.7) (6.7) Net cash used in investing activities (285.9) (378.7) (368.7) Cash flows from financing activities: Borrowings of long-term debt — 164.7 — Repayments of long-term debt — (169.0) (2.3) Principal repayments on finance leases (1.1) (23.3) (0.1) Dividend payments (61.2) (59.1) (57.0) Excise tax payments (4.2) (2.0) — Proceeds from stock-based compensation awards 11.3 25.5 43.9 Employee stock purchase plan contributions 6.9 7.2 7.1 Shares purchased under share repurchase programs (134.0) (560.9) (438.3) Shares repurchased for employee tax withholdings (2.8) (5.7) (12.9) Net cash used in financing activities (185.1) (622.6) (459.6) Effect of exchange rates on cash 22.9 (21.4) 11.4 Net increase (decrease) in cash and cash equivalents 306.7 (369.3) (40.4) Cash, including cash equivalents at beginning of period 484.6 853.9 894.3 Cash, including cash equivalents at end of period $ 791.3 $ 484.6 $ 853.9 Supplemental cash flow information: Interest paid, net of amounts capitalized $ 0.3 $ 0.5 $ 6.0 Income taxes paid, net $ 125.2 $ 71.4 $ 90.8 Accrued capital expenditures $ 37.9 $ 53.0 $ 53.3 Dividends declared, not paid $ 15.8 $ 15.2 $ 14.8 The accompanying notes are an integral part of the consolidated financial statements."},{"id":"e20","sourceId":"filing-2","location":"Unaudited condensed consolidated statements of cash flows / First half 2026","excerpt":"and Subsidiaries (in millions) Six Months Ended June 30, 2026 2025 Cash flows from operating activities: Net income $ 292.8 $ 221.6 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 90.3 79.9 Amortization 1.1 1.5 Stock-based compensation 17.5 8.7 Non-cash restructuring charges 1.9 1.6 Asset impairments 4.2 4.1 Other non-cash items, net (5.0) (6.9) Changes in assets and liabilities (188.9) (4.0) Net cash provided by operating activities 213.9 306.5 Cash flows from investing activities: Capital expenditures (85.9) (146.5) Net cash used in investing activities (85.9) (146.5) Cash flows from financing activities: Borrowings under revolving credit agreements 50.0 — Repayments under revolving credit agreements (50.0) — Principal repayments on finance leases (0.7) (0.5) Excise tax payments (0.8) (4.2) Dividend payments (31.5) (30.3) Proceeds from stock-based compensation awards 12.4 6.0 Employee stock purchase plan contributions 3.9 3.6 Shares purchased under share repurchase programs (454.3) (134.0) Shares repurchased for employee tax withholdings (2.5) (2.5) Net cash used in financing activities (473.5) (161.9) Effect of exchange rates on cash (10.0) 27.0 Net (decrease) increase in cash and cash equivalents (355.5) 25.1 Cash, including cash equivalents at beginning of period 791.3 484.6 Cash, including cash equivalents at end of period $ 435.8 $ 509.7 Supplemental cash flow information: Accrued capital expenditures $ 25.7 $ 35.4 See accompanying notes to condensed consolidated financial statements."},{"id":"e21","sourceId":"filing-2","location":"MD&A / Liquidity and capital measures","excerpt":"Liquidity and Capital Resources The table below presents selected liquidity and capital measures: ($ in millions) June 30, 2026 December 31, 2025 Cash and cash equivalents $ 435.8 $ 791.3 Accounts receivable, net $ 712.0 $ 574.4 Inventories $ 447.4 $ 443.9 Accounts payable $ 252.7 $ 253.7 Debt $ 202.9 $ 202.8 Equity $ 2,990.2 $ 3,176.0 Working capital $ 1,167.0 $ 1,323.3 Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased."},{"id":"e22","sourceId":"filing-3","location":"Proxy / Existing executive compensation practices","excerpt":"​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ WHAT WE DO ​ WHAT WE DO NOT DO ​ ​ ​Target Total Direct Compensation at the 50th percentile of our comparator group companies ​ ​ ​Provide major portion of compensation through performance-based incentives ​ ​ ​Monitor and model executive pay programs through realizable pay-for-performance analyses and tally sheets ​ ​ ​Incorporate in our Change-in-Control (“CIC”) agreements a “double-trigger” feature requiring termination of employment to receive benefits ​ ​ ​Require executive officers to meet West stock ownership guidelines within 5-year period; if not met, ongoing compliance requirements are imposed until ownership guidelines are met ​ ​ ​Maintain compensation recovery (clawback) policies triggered by financial restatement or executive misconduct ​ ​ ​Engage with an independent consultant to review compensation programs and decisions ​ ​ ​ ​No hedging, pledging or engaging in any derivatives trading with respect to our common stock ​ ​ ​No repricing or exchange of awards without shareholder approval ​ ​ ​No individual severance agreements for executive officers other than CEO ​ ​ ​No tax gross-ups related to change in control ​ ​ ​No guaranteed incentive payouts ​ ​ ​No single trigger accelerated vesting of equity awards for executive officers upon a change in control ​ ​ ​No above market returns on deferred compensation plans ​ Say-on-Pay Each year, we hold a shareholder “Say-on-Pay” advisory vote to assess the support for the compensation of our Named Executive Officers (“NEOs”) as disclosed in our Proxy Statement."},{"id":"e23","sourceId":"filing-3","location":"Compensation discussion / Performance stock units","excerpt":"​ Table of Contents Compensation Tables I 51 Performance Stock Units PSUs represent the largest component of our executives’ annual long-term incentive awards and serve as the primary performance-based element of our compensation program."},{"id":"e24","sourceId":"filing-3","location":"Proxy / Summary of 2025 incentive payouts","excerpt":"Green and 153% for the other active NEOs ● 2023-2025 Performance Share Unit (“PSU”) payout: 41% ​ ​ Table of Contents Compensation Tables I 41 ​ WHAT ARE OUR COMPENSATION PRACTICES?"},{"id":"e25","sourceId":"filing-3","location":"Proxy / Shareholder rights, independence and oversight","excerpt":"SHAREHOLDER RIGHTS ​ Independence Proxy access bylaw ​ Ten of our eleven directors are independent Shareholders holding a combined 25% of the Company’s outstanding voting power can call a special shareholders meeting ​ Separate Board Chair and Lead Independent Director roles No dual class of stock or controlling stockholder ​ 100% independent standing Board committees Majority voting in uncontested director elections ​ Regular executive sessions of independent directors No poison pill in place ​ Board-adopted Independence Standards Annual “Say-on-Pay” advisory vote ​ Annual review of director independence by Nominating and Corporate Governance Committee and Lead Independent Director BOARD COMPOSITION ​ ​ Good governance practices Board comprised of directors with an appropriate mix of skills, experiences and perspectives ​ Strong director attendance at 2025 Board and Committee meetings 36% of our Board is gender diverse and 9% of our Board is ethnically diverse ​ Robust Corporate Governance Principles Active Board refreshment includes the addition of three new directors since 2021 ​ Board Tenure Policy with retirement age of 75 ​ OVERSIGHT ​ Securities Trading Policy expressly prohibits speculative trading and hedging transactions in Company securities ​ ​ ​ Comprehensive risk oversight by the Board and its committees facilitated by our Enterprise Risk Management (“ERM”) program and cybersecurity program ​ ​ Board and committee oversight of sustainability matters ​ ​ ​ ​ Director orientation program and continuing educational opportunities ​ ​ ​ ​ ​ Share Ownership Guidelines for executive officers and directors Related Party Transaction Policy and Procedures ​ ACCOUNTABILITY ​ Policy on directors’ outside board service Annual Board and committee self-evaluations ​ ​ ​ Clawback Policy in the event of executive misconduct ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Table of Contents ​ ​ ​ Proxy Summary I 5 Executive Compensation Highlights Our executive compensation program is designed with the objective of strongly linking pay with performance."},{"id":"e26","sourceId":"filing-3","location":"Corporate governance / Board Chair's CEO role","excerpt":"Our Board Chair attends all Board meetings and attends virtually all committee meetings unless there is a scheduling conflict or the meeting concerns matters for which he should be excused, such as his compensation as CEO."},{"id":"e27","sourceId":"filing-3","location":"Compensation discussion / 2025 financial performance","excerpt":"​ ​ 2025 Performance at a Glance ​ ​ ​ ​ ​ ​ $3.1B Net Sales ​ ​ $6.79 Reported-diluted EPS $7.29 Adjusted-diluted EPS* Full-year 2025 net sales of $3.1 billion, a 6.3% increase; organic net sales* increase of 4.3%; currency translation increased net sales by 200 basis points ​ ​ Full-year 2025 reported-diluted EPS of $6.79, an increase of 1.5%, and full-year 2025 adjusted-diluted EPS* of $7.29 increased 8.0% ​ ​ ​ ​ 19.0% ​ Operating Profit Margin 20.2% Adjusted Operating Profit Margin* ​ ​ ​ ​ $755M Operating Cash Flow Full-year 2025 operating profit margin of 19.0%, a decrease of 70 basis points, and full-year 2025 adjusted operating profit margin* of 20.2%, an increase of 40 basis points ​ ​ Full-year 2025 operating cash flow was $755 million, an increase of 15.5%; capital expenditures were $286 million, compared to $377 million over the same period last year; free cash flow (operating cash flow minus capital expenditures) was $469 million, an increase of 70% ​ * See Annex A on Page A-1 for a reconciliation of these non-U.S."},{"id":"e28","sourceId":"filing-2","location":"MD&A / SmartDose demand ahead of transaction closing","excerpt":"The increase in HVP delivery devices was driven primarily by customer demand for our self-injection devices, in particular SmartDose 3.5mL in advance of the July 2026 transaction closing, and sales price increases."},{"id":"e29","sourceId":"filing-2","location":"MD&A / Operating cash flow and working capital","excerpt":"39 Table of Contents FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES Cash Flows The following table presents cash flow data for the six months ended June 30: ($ in millions) 2026 2025 Net cash provided by operating activities $ 213.9 $ 306.5 Net cash used in investing activities $ (85.9) $ (146.5) Net cash used in financing activities $ (473.5) $ (161.9) Net Cash Provided by Operating Activities – Net cash provided by operating activities decreased by $92.6 million for the six months ended June 30, 2026, as compared to the same period in 2025, due primarily to fluctuations in working capital and increased incentive payments, partially offset by improved operating results."}],"changes":["No comparable previous version; previous accepted analysis is null."],"limitations":["Assessment uses only supplied passages. The 10-K, proxy and quarterly report have filed dates of February 17, March 12 and July 23, 2026, respectively; these are filing dates, not retrieval dates.","All evidence is issuer disclosure. Reported financial results substantiate operating outcomes, while leadership, differentiation and customer-trust statements remain management assertions.","Sharp and PCI Pharma Services are explicitly named competitors in expanded contract manufacturing services. They are not established as competitors to West's proprietary component technologies, so the advantage-specific competitor arrays remain empty. Broader competitor coverage and comparative market shares are absent.","No customer-level retention, switching history, supplier replacement costs, license expiry schedule or comparative product qualification evidence is supplied.","Pricing contribution is observed, but customer contracts, renewal terms, pricing rights and price elasticity are undisclosed. Growth and margins also reflect volume, mix, absorption and currency effects.","SmartDose demand ahead of the July 2026 transaction closing may not represent recurring demand. The supplied passages do not establish post-transaction economics.","The proxy provides actual compensation and governance disclosures, but does not establish individual executive ownership compliance in the supplied passages. Annual-meeting proposals are not treated as adopted outcomes.","No evidence establishes network effects, a relative unit-cost advantage or an efficient-scale market structure."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":3,"rationale":"Exclusive proprietary licenses, research capabilities and regulated customer integration support a meaningful current advantage, corroborated by high-value component sales growth. Comparative superiority is unproven.","evidenceIds":["e1","e2","e3","e5","e6"]},{"criterion":"durability","grade":2,"rationale":"Multi-year development and approval processes support persistence, but license duration and replacement economics are missing. Alternative technologies present potential erosion rather than demonstrated displacement.","evidenceIds":["e1","e4","e5","e8"]},{"criterion":"customer_dependency","grade":2,"rationale":"Customer acceptance and regulatory integration imply dependency, while continued component demand provides indirect operating support. Customer-specific repeat orders and actual switching experience are unavailable.","evidenceIds":["e5","e6","e7"]},{"criterion":"erosion_resilience","grade":2,"rationale":"Component demand and realized pricing remain favorable, but cyber downtime caused an actual revenue impact. Technology and quality risks are prospective and do not establish realized moat erosion.","evidenceIds":["e7","e8","e9","e11","e13"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":3,"rationale":"Price increases supported 2025 proprietary operating profit and contributed $30.3 million to second-quarter 2026 consolidated sales growth alongside positive volume and mix. Historical pass-through delays limit the strength of this evidence.","evidenceIds":["e13","e14","e16"]},{"criterion":"retention","grade":2,"rationale":"Growing high-value component sales and continued customer demand alongside price increases indirectly support repeat demand and pricing acceptance. They do not establish customer retention rates or exclude customer losses.","evidenceIds":["e6","e7","e13"]},{"criterion":"margin_resilience","grade":2,"rationale":"First-half 2026 gross profit grew faster than sales, and proprietary profit improved in 2025. However, 2025 reported operating margin declined and contract manufacturing profit fell with higher production costs. These mixed results do not isolate pricing from mix and absorption.","evidenceIds":["e14","e15","e18","e27"]},{"criterion":"contractual_freedom","grade":2,"rationale":"Actual price increases demonstrate some practical discretion, while historical cost pass-through delays reveal constraints. Competitive limits are disclosed as possible, not proven current failures. Contractual repricing rights and customer commitments remain unknown.","evidenceIds":["e13","e16","e17"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"2025 operating cash flow of $754.8 million covered $285.9 million of capital spending and shareholder distributions. In first-half 2026, $454.3 million of buybacks exceeded cash flow after capital expenditure, reducing cash materially, although cash remained above disclosed debt. Investment returns and repurchase value creation are unproven.","evidenceIds":["e19","e20","e21"]},{"criterion":"incentive_alignment","grade":3,"rationale":"Existing ownership guidelines, clawbacks, hedging restrictions and double-trigger protections support alignment. PSUs are the largest annual long-term award component, and the disclosed 41% 2023–2025 PSU payout demonstrates variable outcomes. Individual ownership compliance and full target rigor are not established.","evidenceIds":["e22","e23","e24"]},{"criterion":"execution","grade":2,"rationale":"Actual sales, profits and 2025 cash generation demonstrate delivery, but contract manufacturing profit declined and cyber downtime reduced 2026 revenue. First-half cash conversion weakened, and some device demand preceded a transaction. This assessment uses operating outcomes rather than management reputation.","evidenceIds":["e11","e14","e15","e18","e19","e28","e29"]},{"criterion":"governance","grade":3,"rationale":"Ten of eleven directors are disclosed as independent, standing committees are independent, and shareholders have proxy access, majority voting and special-meeting rights. The combined CEO and Chair role concentrates authority, moderated by a Lead Independent Director. Disclosed structures support a strong grade without proving exceptional oversight effectiveness.","evidenceIds":["e25","e26"]}]}],"qualityPolicy":"quality-scores-2","basisHash":"d34ac35e02f517f227c3da15a6075f53e351c24dac1d1db08d6bbd30551d9484","updatedAt":"2026-10-18T00:23:02.739Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000010/wst-20251231.htm","publishedAt":"2026-02-17","sha256":"41ea0cd1b5b4825c015e74280a54e755e7c6d29c4b10be540683d879f7881d1a","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000099/wst-20260630.htm","publishedAt":"2026-07-23","sha256":"dd1be95561820d403b1a41332455a13e9bdb1c90aef41cf9f924d2a7b000d0df","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/105770/000110465926026778/wst-20260504xdef14a.htm","publishedAt":"2026-03-12","sha256":"0749df6246ef87b21753cd5f7df8be12fda86cb083e454e3d433642a354b8574","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:37cb0bc71b55853c74a9828069c61b743cee3e921dadc8a965f0eed59f5b971f","usage":{"input_tokens":54210,"cached_input_tokens":20992,"cache_write_input_tokens":0,"output_tokens":3338,"reasoning_output_tokens":159}},"signals":[{"period":"2021","end":"2021-12-31","values":{"gross_margin":41.52422658567595,"operating_margin":26.568018081649953,"roic":38.83212728065419,"fcf_margin":11.675377878231389,"sbc_revenue":1.3243395959881339},"issues":{"software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2022","end":"2022-12-31","values":{"gross_margin":39.35709584675603,"operating_margin":25.42519657764384,"roic":31.90198210721476,"fcf_margin":15.220478714191692,"sbc_revenue":0.8209498077522602},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2023","end":"2023-12-31","values":{"gross_margin":38.28056139399281,"operating_margin":22.91680791918096,"roic":26.340753427207268,"fcf_margin":14.051800122042172,"sbc_revenue":0.7898840599362668},"issues":{"pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2024","end":"2024-12-31","values":{"gross_margin":34.51195907645514,"operating_margin":19.697912346191067,"roic":20.079591671337745,"fcf_margin":9.553435642195494,"sbc_revenue":0.6463431494538919},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2025","end":"2025-12-31","values":{"gross_margin":35.91295013174588,"operating_margin":19.02670700367587,"roic":18.707157863255905,"fcf_margin":15.253244852151848,"sbc_revenue":0.7742103379851014},"issues":{"software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000010/wst-20251231.htm","publishedAt":"2026-02-17","sha256":"41ea0cd1b5b4825c015e74280a54e755e7c6d29c4b10be540683d879f7881d1a","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000099/wst-20260630.htm","publishedAt":"2026-07-23","sha256":"dd1be95561820d403b1a41332455a13e9bdb1c90aef41cf9f924d2a7b000d0df","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/105770/000110465926026778/wst-20260504xdef14a.htm","publishedAt":"2026-03-12","sha256":"0749df6246ef87b21753cd5f7df8be12fda86cb083e454e3d433642a354b8574","dateKind":"filed"}],"history":[{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"narrow","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"narrow","value":null},{"version":1,"updatedAt":"2026-10-18T02:18:02.026Z","verdict":null,"value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}